MedPath
HSA Approval

BONJESTA EXTENDED-RELEASE TABLETS 20 MG/20 MG

SIN16865P

BONJESTA EXTENDED-RELEASE TABLETS 20 MG/20 MG

BONJESTA EXTENDED-RELEASE TABLETS 20 MG/20 MG

September 18, 2023

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

Regulatory Information

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

Therapeutic

Prescription Only

Formulation Information

TABLET, FILM COATED, EXTENDED RELEASE

**2\. DOSAGE AND ADMINISTRATION** **2.1 Dosage Information** Initially, take one BONJESTA extended-release tablet orally at bedtime (Day 1). If this dose adequately controls symptoms the next day, continue taking one tablet daily at bedtime only. However, if symptoms persist on Day 2, increase the daily dose to one tablet in the morning and one tablet at bedtime. The maximum recommended dose is two tablets per day, one in the morning and one at bedtime. Take on an empty stomach with a glass of water _\[see Clinical Pharmacology (11.2)_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_. Swallow tablets whole. Do not crush, chew, or split BONJESTA tablets. Take daily and not on an as needed basis. Reassess the woman for continued need for BONJESTA as her pregnancy progresses.

ORAL

Medical Information

**1\. INDICATIONS AND USAGE** BONJESTA is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. **Limitations of Use** BONJESTA has not been studied in women with hyperemesis gravidarum.

**4\. CONTRAINDICATIONS** BONJESTA is contraindicated in women with any of the following conditions: - Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation - Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of BONJESTA _\[see Drug Interactions (7.1)_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.

R06AA59

doxylamine, combinations

Manufacturer Information

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

Duchesnay Inc.

Active Ingredients

Doxylamine Succinate

20.0mg

Doxylamine

Pyridoxine HCl

20.00mg

Pyridoxine

Documents

Package Inserts

Bonjesta PI.pdf

Approved: December 11, 2023

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.